In the SHARP trial, patients with uHCC included:
Child-Pugh class A (95%), class B (5%)
ECOG performance status 0-2
Portal vein invasion/extrahepatic spread (with or without)
Broad range of demographics
Europe and Australasia (88%)
North America (9%)
Central and South America (3%)
BCLC stage B and C
because of inadequate hepatic
reserve or tumor location
Inoperable because of
performance status or
comorbidity, local disease, or
local disease with minimal
extrahepatic disease only
HCC with metastatic
disease or extensive liver
National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
STIVARGA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Severe and sometimes fatal hepatotoxicity has occurred in clinical trials.
Monitor hepatic function prior to and during treatment.
Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.
Continue reading below